Virginia Morello

Virginia obtained a MSc degree in Molecular Biotechnology and a PhD in Biomedical Sciences and Human Oncology, both from the University of Torino, Italy. In 2011 she joined the laboratory of Experimental Therapy at the University of Torino, led by Paolo Michieli. Virginia actively collaborated with argenx on the preclinical characterization of ARGX-111, a MET-antagonistic antibody that is now being tested in the clinic. After completing this project, she started working on the physiological role of HGF/MET signaling in tissue regeneration. In particular, she focused her research on the development and characterization of HGF-mimetic antibodies and in their preclinical validation in different mouse models of disease. In 2016 Virginia co-founded EuremAb, a University of Torino spin-off company specialized in therapeutic antibodies and mouse models of disease. In 2017 she co-founded AgomAb together with team colleagues at the University of Torino and long-established collaborators at argenx.